Salud financiera de hoja de balance de Vertex Pharmaceuticals

Salud financiera controles de criterios 6/6

Vertex Pharmaceuticals tiene un patrimonio de accionistas total de $18.5B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $23.9B y $5.4B respectivamente. El BAIT de Vertex Pharmaceuticals es de $4.4B, por lo que su ratio de cobertura de intereses es de -7. Tiene efectivo e inversiones a corto plazo que ascienden a $10.2B.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	-6.5x
Efectivo	US$5.80b
Patrimonio	US$14.77b
Total pasivo	US$5.36b
Activos totales	US$20.13b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($14.1B) de VRTX34 superan a sus pasivos a corto plazo ($3.5B).

Pasivo a largo plazo: Los activos a corto plazo de VRTX34 ($14.1B) superan a sus pasivos a largo plazo ($1.6B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: VRTX34 está libre de deudas.

Reducción de la deuda: VRTX34 no tenía deudas hace 5 años.

Cobertura de la deuda: VRTX34 no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: VRTX34 no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Salud financiera de hoja de balance de Vertex Pharmaceuticals

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations

Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024

Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director

Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024

Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024

Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024

Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain

Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024

Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi

Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation

Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023

Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors

Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5

Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine

Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old

Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares.

Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023

Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022

Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022

Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022

Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months

Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022

Vertex Advances VX-548 in Acute and Neuropathic Pain

Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million.

Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA

Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director

Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022

Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022

Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022

Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

Vertex Pharmaceuticals Incorporated Announces Reimbursement Agreement in Australia for TRIKAFTA

Vertex Pharmaceuticals Incorporated Provides Full Year 2022 Financial Guidance

Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor)

Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis

Vertex Pharmaceuticals Incorporated Announces Its Supplement to a New Drug Submission for PrKALYDECO

Vertex Pharmaceuticals Incorporated Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis

Vertex Pharmaceuticals Incorporated Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $1,500 million worth of its shares.

Health Canada Grants Marketing Authorization for Vertex Pharmaceuticals Incorporated TRIKAFTA®

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy